Flutialfa S 125 Inhaler is a combination of Salmeterol (25mcg) and Fluticasone Propionate (125mcg), designed for the effective management of asthma and chronic obstructive pulmonary disease (COPD). This dual-action inhaler provides long-lasting bronchodilation and anti-inflammatory effects, ensuring optimal respiratory health. Salmeterol, a long-acting beta-2 agonist (LABA), works by relaxing the smooth muscles of the airways, promoting airflow and reducing breathlessness. Fluticasone Propionate, a corticosteroid, minimizes inflammation in the airways, helping to prevent asthma attacks and flare-ups.
The Flutialfa S 125 Inhaler is particularly effective in controlling symptoms such as wheezing, coughing, and chest tightness, while also reducing the frequency and severity of exacerbations. Regular use improves lung function, enhances quality of life, and ensures better symptom control for individuals with moderate to severe asthma or COPD. The metered-dose inhaler format ensures precise delivery of medication directly to the lungs, maximizing therapeutic benefits and minimizing systemic side effects.
This inhaler is an integral part of respiratory care, offering both immediate and long-term relief for individuals requiring comprehensive management of chronic respiratory conditions.